FGFR2 and gastric cancer: Fibroblast Growth Factor Receptor 2 (FGFR2) was regarded as a promising target for GC, and there has been an increasing number of small molecule inhibitors and monoclonal antibodies targeting FGFR2 that have entered into clinical trials (Tojjari et al., 2024).